

In the claims:

Please enter the following amendments to the claims

14. (Amended) The amplification oligonucleotide primer of claim 11, wherein said oligonucleotide comprises a sequence selected from the group consisting of
5'-CTCGGCCCTGCACTGTTTC-3' (SEQ ID NO. 1),
5'-GCTTGTCAGAGACCCTTG-3' (SEQ ID NO. 2),
5'-CTCGGAAGAGCAGGATTGCGTA-3' (SEQ ID NO. 3),
5'-CCTGACCCAGCTGGATGAG-3' (SEQ ID NO. 4), and
5'-CTTCCCTGAGTGCAAAGGCG-3' (SEQ ID NO. 5).

REMARKS

The amendments to the claims above are submitted to conform the claims to the SEQ ID NO. references and not for any reason related to patentability. No new matter is added by the amendments.

Clean copies of the amended paragraph of the specification and the amended claim are attached as Appendices 1 and 2 respectively.

CONCLUSION

Applicants respectfully submit that the pending claims are in condition for allowance. An early notice to that effect is earnestly solicited. Should any matters remain outstanding, the Examiner is encouraged to contact the undersigned at the address and telephone number listed below so that they may be resolved without the need for additional action and response thereto.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check